Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata’s licensing partner, Catalent, Inc. (“Catalent”), at the 16^th Annual World ADC San Diego Conference, held November 3-6, 2025. Catalent’s presentation included data demonstrating the positive impact of incorporating Lisata's proprietary iRGD cyclic peptide product candidate, certepetide, and its analogs as a payload in Catalent’s SMARTag^® antibody-drug conjugate (“ADC”) technology platform. Specifically, Catalent reported preclinical results showing that using certepetide as a non-cytotoxic ADC payload not only improved ADC efficacy but also broadened the distribution of the cytotoxic payload within the tumor microenvironment. A summary of these results can be found here in the Company’s latest corporate presentation.